FDA Approves Keytruda (pembrolizumab) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma
KENILWORTH, N.J.--(BUSINESS WIRE) June 11, 2019 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, as...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Canada Health | Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Food and Drug Administration (FDA) | HNSCC | Merck | Skin Cancer | Squamous Cell Carcinoma | USA Health